Combined inhibition of AIF/CHCHD4 interaction and GLS1 to exploit metabolic vulnerabilities in pediatric osteosarcoma

This study identifies the AIF/CHCHD4 complex as a druggable target in pediatric osteosarcoma and demonstrates that combining mitoxantrone, which inhibits this complex, with the glutaminase inhibitor telaglenastat synergistically overcomes chemoresistance by exploiting metabolic vulnerabilities.

The Gist

The Big Picture: A New Strategy for a Tough Cancer

Osteosarcoma is a dangerous bone cancer that mostly affects teenagers and young adults. While doctors can often cure it if caught early, it becomes very hard to treat once it spreads (metastasizes) or comes back after treatment. The current "standard" drugs often stop working because the cancer cells learn how to resist them.

This paper is about finding a new way to trick these stubborn cancer cells into dying. The researchers didn't invent a brand-new drug; instead, they found a clever way to use an old drug (Mitoxantrone) in a new way, and then paired it with a second drug (Telaglenastat) to create a "one-two punch" that works better than either drug alone.

---

The Story in Three Acts

Act 1: Finding the Weak Spot (The "Factory Manager")

Imagine a cancer cell as a busy factory. Inside this factory, there is a critical machine called the Mitochondria (the power plant). To keep the power plant running, the factory needs a specific "manager" team to assemble the machinery. This team consists of two proteins: AIF and CHCHD4. They work together like a lock and key to ensure the factory's power generators are built correctly.

• The Discovery: The researchers screened thousands of existing drugs to see if any could break this "lock and key" connection. They found Mitoxantrone (a drug already used for leukemia and breast cancer).
• The Analogy: Think of Mitoxantrone as a grease spill that gets between the gears of the manager team. It stops AIF and CHCHD4 from holding hands. Without this team, the factory's power plant starts to fall apart. The generators (energy production) break down, and the factory starts to malfunction.

Act 2: The Cancer's Desperate Gamble (The "Glutamine Hoard")

When the cancer cell realizes its power plant is broken, it panics. It tries to find a workaround to survive.

• The Reaction: The cell starts hoarding a specific fuel called Glutamine. Normally, cells use Glutamine to make energy. But in this case, the broken power plant can't use it for energy. Instead, the cell starts using the Glutamine to build nucleotides (the building blocks of DNA) to try to repair itself and keep dividing.
• The Metaphor: Imagine a car with a broken engine. Instead of fixing the engine, the driver starts stuffing the trunk with extra gas cans, thinking, "If I have enough gas, maybe I can just push the car to the finish line." The cancer cell is essentially hoarding fuel to build more copies of itself, hoping to outsmart the damage.

Act 3: The Trap (The "Double Whammy")

The researchers realized that while the cancer cell was busy hoarding Glutamine to build DNA, it was actually walking into a trap.

• The Strategy: They took the first drug (Mitoxantrone) to break the power plant, forcing the cell to hoard Glutamine. Then, they added a second drug called Telaglenastat.
• The Analogy: Telaglenastat is like a lock on the gas pump. It stops the cell from processing the Glutamine it just hoarded.
• The Result: The cancer cell is now in a nightmare scenario:
  1. Its power plant is broken (thanks to Mitoxantrone).
  2. It has a trunk full of gas (Glutamine) it can't use.
  3. The gas pump is locked (thanks to Telaglenastat).
  4. It can't build new DNA to survive.

The cell runs out of options and dies.

What Did They Prove?

1. In the Lab: When they treated cancer cells with both drugs together, the cells died much faster than with just one drug. Even cells that were resistant to other chemotherapy drugs were killed by this combination.
2. In Mice: They tested this on mice with human osteosarcoma tumors.
   • Mice treated with Drug A alone? The tumors kept growing.
   • Mice treated with Drug B alone? The tumors kept growing.
   • Mice treated with both? The tumors shrank significantly.

Why This Matters

This is a great example of Drug Repurposing. Instead of spending 10 years and billions of dollars to invent a totally new chemical, the researchers took a drug we already know is safe (Mitoxantrone) and figured out a new way to use it.

By understanding how the cancer tries to survive (by hoarding Glutamine), they found a way to block that escape route. This gives hope that we can treat aggressive, drug-resistant bone cancer by hitting it from two different angles at once.

The Bottom Line

The researchers found a way to break the cancer's "power plant" and then block its "emergency backup fuel." This combination forces the cancer to starve itself, offering a promising new path to treat osteosarcoma that has stopped responding to standard chemotherapy.

Technical Summary

1. Problem Statement

Clinical Context: Pediatric osteosarcoma is an aggressive bone tumor with a high rate of metastatic relapse and poor survival outcomes (dropping from ~75% to ~20% in metastatic cases) due to primary and acquired chemoresistance. Standard treatments (surgery + multi-agent chemotherapy) have not significantly improved in decades.
Scientific Gap: There is an urgent need for novel therapeutic strategies that target metabolic reprogramming and mitochondrial dysfunction, which are hallmarks of osteosarcoma progression. Specifically, the role of the mitochondrial Apoptosis-Inducing Factor (AIF) and its partner CHCHD4 in regulating mitochondrial electron transport chain (mETC) assembly and metabolism remains under-exploited as a druggable target.
Objective: To identify small molecules that disrupt the AIF/CHCHD4 complex, characterize the resulting metabolic vulnerabilities in osteosarcoma, and develop a synergistic combination therapy to overcome chemoresistance.

2. Methodology

The study employed a multi-disciplinary approach combining high-throughput screening, computational biology, molecular biology, metabolomics, and in vivo models.

• High-Throughput Screening (HTS): A robotized AlphaScreen assay was used to screen a library of 1,280 off-patent small molecules (Prestwick Chemicals) for their ability to disrupt the interaction between recombinant HIS-AIF and GST-CHCHD4.
• Computational Modeling: Molecular dynamics (MD) simulations and blind docking (AutoDock Vina) were performed on the human AIF monomer structure to predict the binding mode of the identified hit.
• Cell Models:
  • In Vitro: Eight pediatric osteosarcoma cell lines (including parental and drug-resistant variants like HOS-R/DOXO and HOS-R/MTX) and 11 secondary Patient-Derived Xenograft (PDX) cultures derived from refractory/relapsed patients.
  • Genetic Manipulation: CRISPR-Cas9 was used to generate MICU1 knockout (KO) and overexpression (OE) clones to validate the role of MICU1 (a substrate of the AIF/CHCHD4 system). siRNA was used to knock down AIF.
• Functional Assays:
  • Cytotoxicity: LDH assays and clonogenic assays to determine IC50 values.
  • Mitochondrial Function: Seahorse XF analysis (OCR, glycolysis, fatty acid oxidation), ATP assays, TMRM flow cytometry (membrane potential), and Rhod-2 imaging (Ca²⁺ uptake).
  • Protein Analysis: Co-immunoprecipitation (Co-IP) to verify complex disruption; Western blotting for mETC complexes, MICU1, COX17, and GLS1.
  • Metabolomics: UHPLC-MS/MS and GC-MS/MS profiling to map metabolic shifts.
• Synergy Testing: The SynergyFinder platform (HSA model) was used to evaluate drug combinations.
• In Vivo Studies: NSG mice bearing U2OS-Luc/mKate2 xenografts were treated with Mitoxantrone, Telaglenastat (GLS1 inhibitor), or their combination. Tumor volume and bioluminescence were monitored.

3. Key Contributions

1. Discovery of Mitoxantrone as an AIF/CHCHD4 Inhibitor: Identified the clinically approved drug mitoxantrone (an anthracenedione) not just as a DNA intercalator, but as a specific inhibitor of the AIF/CHCHD4 mitochondrial import machinery.
2. Mechanistic Insight: Demonstrated that mitoxantrone binds to the NADH pocket of AIF, competitively inhibiting NAD binding and preventing AIF dimerization, which disrupts the disulfide relay system required for the oxidative folding of mitochondrial proteins.
3. Metabolic Reprogramming Characterization: Uncovered a specific metabolic vulnerability induced by AIF/CHCHD4 disruption: glutamine accumulation and a compensatory shift toward nucleotide biosynthesis.
4. Therapeutic Strategy: Validated a synergistic combination of mitoxantrone (AIF/CHCHD4 inhibitor) and telaglenastat (GLS1 inhibitor) that overcomes chemoresistance in osteosarcoma models.

4. Key Results

A. Identification and Mechanism of Mitoxantrone

• Screening: Mitoxantrone was identified as a top hit disrupting the AIF/CHCHD4 interaction (IC50 ~10 µM in SPR assays).
• Binding Mode: Computational docking suggested mitoxantrone binds to the NADH pocket of AIF, stabilizing interactions with residues Phe190, Val378, and others, thereby blocking NAD binding.
• Specificity: Co-IP confirmed that mitoxantrone disrupts the AIF/CHCHD4 complex. Knockdown of AIF reduced mitoxantrone's cytotoxicity, confirming AIF as the primary target.

B. Impact on Mitochondrial Function

• Protein Depletion: Treatment led to the time-dependent depletion of AIF/CHCHD4 substrates, specifically MICU1 (calcium uptake regulator) and COX17 (mETC assembly), as well as Complex I (CI) and Complex IV (CIV) of the electron transport chain.
• Bioenergetics: Despite reduced Oxygen Consumption Rate (OCR) and proton leak, cells exhibited mitochondrial hyperpolarization (increased ΔΨm) and increased ATP levels, indicating a shift to a high-potential, low-respiration state.
• Calcium Handling: Mitoxantrone treatment increased mitochondrial Ca²⁺ uptake capacity, a phenotype mimicked by MICU1 knockout, suggesting MICU1 downregulation drives this change.
• Ultrastructure: Transmission electron microscopy revealed mitochondrial swelling and cristolysis (loss of cristae).

C. Metabolic Vulnerability and Glutamine Addiction

• Metabolomics: Mitoxantrone treatment caused a significant accumulation of glutamine and an increase in the glutamate/glutamine ratio, alongside upregulation of GLS1 (glutaminase 1).
• Pathway Shift: While fatty acid oxidation (FAO) was initially enriched, cells became insensitive to FAO inhibitors (etomoxir). Instead, glutamine was redirected away from the TCA cycle and glutathione synthesis toward nucleotide biosynthesis (purine and pyrimidine pathways).
• Rescue Assay: The cytotoxicity of the mitoxantrone/telaglenastat combination was reversed by the addition of exogenous nucleosides, confirming that the synthetic lethality is driven by nucleotide starvation.

D. Synergistic Combination Therapy

• In Vitro Synergy: The combination of mitoxantrone and telaglenastat showed strong synergism (SynergyFinder score >10) in multiple osteosarcoma cell lines (HOS, U2OS, SAOS2), including drug-resistant variants.
• In Vivo Efficacy: In NSG mice with established U2OS tumors:
  • Monotherapy with either drug at low doses showed minimal tumor growth inhibition.
  • Combination therapy significantly reduced tumor volume (approx. 696 mm³ vs. ~1100–1268 mm³ in controls/monotherapies) without significant toxicity.
  • Bioluminescence imaging confirmed reduced tumor burden in the combination group.

5. Significance and Conclusion

• Drug Repurposing: This study redefines mitoxantrone's mechanism of action, highlighting its ability to target mitochondrial protein import machinery, offering a new avenue for treating chemoresistant osteosarcoma.
• Metabolic Targeting: It establishes a clear link between mitochondrial dysfunction (AIF/CHCHD4 disruption) and a compensatory metabolic shift toward glutamine-dependent nucleotide synthesis.
• Clinical Potential: The combination of an AIF/CHCHD4 inhibitor (mitoxantrone) and a GLS1 inhibitor (telaglenastat) represents a promising, rational strategy to overcome metabolic adaptations and chemoresistance in pediatric osteosarcoma.
• Broader Implications: The concept of inducing a "glutamine-nucleotide coping mechanism" via mitochondrial disruption may be applicable to other cancer types, suggesting a broader therapeutic paradigm for targeting metabolic vulnerabilities.

Limitations Noted: The precise biophysical binding mechanism requires crystallography/cryo-EM validation; the specific steps of glutamine-to-nucleotide conversion need further definition; and in vivo validation is currently limited to one xenograft model.